Transforming Medicine
with Proven Products

Heart Failure Diuresis –
Where and When Needed

Our advanced precision pump technology enables cost-effective subcutaneous administration
of pharmaceuticals.

Taking the PICC
out of OPAT

Our convenient sc2Wear™ Infusor enables subcutaneous anytime anywhere delivery of drugs
that now require intravenous or intramuscular administration.

We are a pharmaceutical company developing a new and better way to administer some of the most important drugs used in medicine.

Heart Failure

Improving heart failure outcomes with the subcutaneous administration of furosemide.

Infectious Disease

Revolutionizing outpatient parenteral antibiotic therapy treatment by means of subcutaneous delivery.

Why scPharmaceuticals

Changing the Heart Failure Treatment Paradigm with the sc2Wear™ Infusor

scPharmaceuticals - working to enable better care for less through the subcutaneous administration of proven pharmaceuticals.

Learn More

News

Go to News & Events
4/26/17

John Tucker Appointed as Chief Executive Officer of scPharmaceuticals

FOR IMMEDIATE RELEASE: LEXINGTON, MA., —scPharmaceuticals, Inc., a privately held biopharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, today announced the appointment of John Tucker as president and chief executive officer, effective immediately.

1/24/17

scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product

FOR IMMEDIATE RELEASE: LEXINGTON, MA., —scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN).

1/4/17

scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

FOR IMMEDIATE RELEASE: LEXINGTON, MA. — scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round.